Yasir M. Nagarwala

Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling

Frankie A. Holmes, Virginia Espina, Lance A. Liotta et al. · BMC Research Notes · 2013 · 74 citations · Full text

Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.

Karen A. Gelmon, Frances Boyle, Bella Kaufman et al. · Journal of Clinical Oncology · 2012 · 68 citations

Surgical Oncology, Breast Oncology, Open-label Phase Iii +17

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors

Matthew D. Galsky, Daniel D. Von Hoff, Marcus A. Neubauer et al. · Investigational New Drugs · 2010 · 64 citations

Tumoral Pathology, Malignant Disease, Randomized Discontinuation Study +8

Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.

F. A. Holmes, Yasir M. Nagarwala, Virginia Espina et al. · Journal of Clinical Oncology · 2011 · 48 citations

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma

Meletios Α. Dimopoulos, Arlene S. Swern, J S Li et al. · Blood Cancer Journal · 2014 · 44 citations · Full text

Hematological Malignancy, Oncology, Immunodeficiencies +14